Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | NMT1 | P30419 | 5/20 | 0.47 |
| ▸ | NMT2 | O60551 | 4/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.44 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630712 | 1.00 | FOLH1 (0.51) | FOLH1GSRNMT1NMT2TLR2 | |
| SCHEMBL29591207 | 0.98 | FOLH1 (0.50) | FOLH1GSRNMT1NMT2TLR2 | |
| SCHEMBL30373815 | 0.98 | FOLH1 (0.50) | FOLH1GSRNMT1NMT2TLR2 | |
| SCHEMBL29669224 | 0.98 | FOLH1 (0.50) | FOLH1GSRNMT1NMT2TLR2 | |
| SCHEMBL29630412 | 0.98 | FOLH1 (0.50) | FOLH1GSRNMT1NMT2TLR2 | |
| SCHEMBL29630730 | 0.98 | FOLH1 (0.50) | FOLH1GSRNMT1NMT2TLR2 | |
| SCHEMBL30445726 | 0.95 | NMT1 (0.49) | FOLH1GSRNMT1NMT2TLR2 | |
| SCHEMBL30336991 | 0.95 | FOLH1 (0.53) | FOLH1GSRNMT1NMT2TLR2 | |
| SCHEMBL30373236 | 0.95 | FOLH1 (0.53) | FOLH1GSRNMT1NMT2TLR2 | |
| SCHEMBL18806290 | 0.95 | FOLH1 (0.55) | FOLH1GSRCPB2SLC15A2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240353410-A1 | FRET ENZYMATIC SUBSTRATE AND USES THEREOF IN LIVER CANCER | URTESTE S.A. (PL) | 2024-10-24 | — | — | US | disclosed |
| EP-4427041-A1 | FRET ENZYMATIC SUBSTRATE AND USES THEREOF IN LIVER CANCER | Urteste S.A. (PL) | 2024-09-11 | — | — | EP | disclosed |
| CN-118202246-A | FRET enzyme substrate and application thereof in liver cancer | 尔特斯特公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023080800-A1 | FRET ENZYMATIC SUBSTRATE AND USES THEREOF IN LIVER CANCER. | URTESTE S.A. (PL) | 2023-05-11 | — | — | WO | disclosed |
| US-20230123431-A1 | METABOLIC ENGINEERING FOR PRODUCTION OF LIPOIC ACID | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-04-20 | — | — | US | disclosed |
| US-11566256-B2 | Polynucleotides and polypeptides in plants | MENDEL BIOTECHNOLOGY, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| CN-115605579-A | Metabolic engineering for the production of lipoic acid | 新加坡国立大学（SG） | 2023-01-13 | — | — | CN | disclosed |
| US-20220325072-A1 | ZWITTERIONIC CROSSLINKERS, HYDROGELS COMPRISING ZWITTERIONIC CROSSLINKERS, AND METHODS FOR MAKING AND USING | UNIVERSITY OF IDAHO | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220325072-A1 | ZWITTERIONIC CROSSLINKERS, HYDROGELS COMPRISING ZWITTERIONIC CROSSLINKERS, AND METHODS FOR MAKING AND USING | ASS1, GFER, ASIC1 | FOLH1 3483/4885GSR 1926/4885NMT1 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.